Korean pharma seeks closer ties with Japan at Asia's largest biotech show
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
YOKOHAMA, Japan — Korean biopharmaceutical companies are scoping out new deals at Bio Japan 2024, Asia’s largest biopharmaceutical trade show, which kicked off its three-day journey on Wednesday amid growing U.S.-China tension in the biotech sector.
Firms including Samsung Biologics and Lotte Biologics are taking part in this year's fair, which runs through Friday at Pacifico Yokohama Exhibition Hall in Yokohama, south of Tokyo, in the heart of the world’s third-largest pharmaceutical market.
Aside from Japan, Korea and Taiwan are the two most prominent participants in the show, which began in 1986 and is the world’s longest-running biotechnology exhibition. About 1,480 organizations from 36 countries are taking part this year, with about one-third of the total participants coming from outside Japan, according to Japan Bioindustry Association (JBL), which hosts the annual event. A relatively small number of Chinese companies, including WuXi AppTec.
Samsung Biologics, a participant since 2022, is a potential beneficiary of the Biosecure Act that recently passed the U.S. House of Representatives, which aims to prevent U.S. government-funded medical providers from doing business with Chinese companies such as WuXi AppTec and WuXi Biologics.
Korean biotech players have certainly been expanding their presence at Bio Japan, Yoshiaki Tsukamoto, executive director of JBL, told press during the exhibition on Wednesday.
“JBL has a lot of collaboration going on with Korea,” Tsukamoto said.
Tsukamoto Korea's fast and talented work force as its key strengths, emphasizing that many of the country's citizens “have abundant experience studying overseas, such as in the United States, which leads to new innovations.”
The executive director suggested that the Biosecure Act could create new business opportunities for Japan if companies take a strategic approach, though he noted that the situation remains unpredictable.
JBL and Korea Biotechnology Industry Organization signed a memorandum of understanding regarding “mutual and communication and partnership” at last year's Bio Japan. The two nations have been making efforts to strengthen their relationship in the biotech sector since last year after a historic series of meetings between President Yoon Suk Yeol and Japanese Prime Minister Fumio Kishida.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- 'Culinary Class Wars' crowns first-ever winner in debut season — spoilers inside
- CU to sell Chef Napoli Matfia's tiramisu from 'Culinary Class Wars'
- From celebrity chef to dim sum queen: Meet the Top 8 of 'Culinary Class Wars' (Part 1)
- From maniac to 'matfia': Meet the Top 8 of 'Culinary Class Wars' (Part 2)
- NCT's Moon Tae-il indicted for alleged sexual assault of woman with two other men
- Netflix's 'Culinary Class Wars' stirs up 148% spike in reservations at chefs' restaurants
- Top 8 reflect on the meaning of 'Culinary Class Wars' ahead of finale
- North Korea detected building nuclear submarine, South's military says
- 2NE1's long-awaited 'Welcome Back' concert gives fans nostalgia overload
- K-pop agencies agree to comply with potential choreography copyright guidelines